Full Breakdown
Ethical Concerns Surround U.S.-Funded Hepatitis B Vaccine Trial in Guinea-Bissau
2/13/2026, 2:33:12 AM
Overview of the Controversial Trial
A proposed U.S.-funded clinical trial assessing the hepatitis B vaccine in Guinea-Bissau has sparked significant ethical debate. The World Health Organization (WHO) Director-General, Tedros Adhanom Ghebreyesus, labeled the study as “unethical” during a recent news conference, emphasizing that denying half of the participating infants a proven vaccine intervention poses serious ethical concerns. The trial aims to evaluate the broader health impacts of administering a birth dose of the hepatitis B vaccine, which has been a standard practice in many countries for over 40 years.
Background and Context
The hepatitis B vaccine is crucial for preventing chronic infections, particularly in newborns who face a 90% risk of chronic infection if exposed to the virus. The Centers for Disease Control and Prevention (CDC) recently shifted its policy, recommending that only infants born to mothers with known hepatitis B infection receive the vaccine at birth, while other infants should receive their first dose at two months. Guinea-Bissau, which has a high prevalence of hepatitis B—nearly 19% of adults are infected—had planned to implement a birth dose policy by 2028, but the trial seeks to investigate the vaccine's effects before this policy takes effect.
Study Design and Objectives
The trial, involving approximately 14,500 infants, would randomly assign half to receive the hepatitis B birth dose and the other half to receive the first dose at the standard two-month mark. The researchers, led by Christine Stabell Benn from the University of Southern Denmark, argue that the study will not deprive any child of necessary vaccinations, as all participants will receive routine vaccines. The primary focus of the trial is to assess potential adverse health effects associated with the birth dose rather than its effectiveness against hepatitis B.
Official Statements & Responses
While Tedros has voiced strong opposition to the trial, stating, “Denying half the children in the trial an intervention that has been proven to be safe and effective would be unethical,” the U.S. Department of Health and Human Services (HHS) defended the study. HHS spokesperson Emily Hilliard stated that the research aims to fill evidence gaps to inform global hepatitis B vaccine policy, adhering to high scientific and ethical standards. Stabell Benn reiterated that the study does not question the vaccine's established effectiveness but seeks to evaluate its broader health implications.
Criticism & Opposition
Critics have raised concerns about the relevance of findings from Guinea-Bissau to the U.S. context, questioning the applicability of the study's outcomes given the differences in vaccination practices. Additionally, the new administration in Guinea-Bissau has expressed objections to the trial protocol, casting further uncertainty on its future. The trial has not yet been registered on clinicaltrials.gov, raising questions about its initiation.
Conflicting Reports & Gaps
The status of the trial remains unclear, with conflicting reports regarding its approval and commencement. While HHS and the researchers assert that the trial will proceed, the lack of registration and the new government's objections suggest potential delays or changes to the study's design.
Verbatim Quotes
“From WHO’s side, the position is very clear. But the country can proceed, knowing full well that it’s unethical,” — Tedros Adhanom Ghebreyesus, WHO Director-General
“The study does not question the vaccine’s effectiveness against hepatitis B infection, which is well established,” — Christine Stabell Benn, Co-Principal Investigator
“This research aims to fill existing evidence gaps to help inform global hepatitis B vaccine policy and is based on the highest scientific and ethical standards,” — Emily Hilliard, HHS Spokesperson
